Abstract Body

In sub-Saharan Africa, 20-25% of those starting ART have CD4<100 cells/ul; ~10% die within 3 months. We investigated the contribution and timing of different causes of mortality/morbidity in the REALITY trial (ISRCTN43622374).

Patients starting ART were randomized to enhanced-prophylaxis against infections (cotrimoxazole [CTX] plus 12 weeks isoniazid+fluconazole, single-dose albendazole, 5-days azithromycin (AZ); Px+) vs CTX alone. Events and causes of death were adjudicated by an endpoint review committee blind to randomization, as (non-mutually exclusively) TB, cryptococcus, severe bacterial infection (SBI; septicaemia, meningitis, pneumonia), other infections potentially responsive to AZ (eg diarrhoea, malaria, encephalitis, toxoplasmosis), other events, and unknown (deaths only).

Median pre-ART CD4 was 37 cells/ul. 225(12.7%) of 1805 patients died by week-48. Most fatal/non-fatal events occurred early (median 4.0 (IQR 2.0-11.7) weeks) after ART initiation, then rates declined exponentially. 154 deaths were adjudicated as having single and 71 multiple causes, which included TB in 80(4.5%) patients, cryptococcus 20(1.1%), SBI 33(1.9%), other potentially-AZ-responsive infections 23(1.3%), other causes 63(3.6%) and unknown causes 88(5.0%). Considering the incidence of first fatal/non-fatal events through week-48, TB was diagnosed in 10.9%, cryptococcus 2.5%, SBI 5.1%, other potentially-AZ-responsive infections 3.6% and other events 27.0%. Px+ reduced deaths from cryptococcus (p=0.03) and unknown causes (p=0.03) but not deaths from TB (p=0.34), SBI (p=0.90), other potentially-AZ-responsive infections (p=0.31) or other causes (p=0.66). Px+ reduced the incidence of non-fatal/fatal TB (p=0.007) and cryptococcus (p=0.03) but not SBI (p=0.26), other potentially-AZ-responsive infections (p=0.34) or other events (p=0.81). By 48 weeks, event rates were lowest (<1 per 100 person-years [PY]) for cryptococcus, moderate (1–5 per 100 PY) for TB, SBI, potentially AZ-responsive infections and unknown deaths, and highest (>5 per 100PY) for other events. Median last post-baseline VL before death was 105 c/ml (N=140); CD4 was 59 cells/ul.

Enhanced prophylaxis reduced mortality and the incidence of TB and cryptococcus in those with CD4 <100 cells/ul. The high early incidence of both opportunistic and non-opportunistic infections highlights the need for a broad Px+ bundle at the same time as ART initiation in those with advanced HIV disease.